AbbVie Reports Positive Phase 3 Results for Epkinly in Large B-Cell Lymphoma
AbbVie announced positive phase 3 trial results showing that its experimental drug Epkinly, when combined with Revlimid, improved progression-free survival in patients with large B-cell lymphoma who had previously failed at least one therapy. The data could support regulatory submissions and potentially expand treatment options for this patient population.
Tickers: $ABBV
Topics: bispecific antibodies lymphoma pharmaceuticals progression-free survival